Navigation Links
Genzyme Reports Strong First-Quarter Growth
Date:4/23/2008

y participants were encouraging. Genzyme expects to release

results by mid year for a larger number of patients, including results

for those patients who have completed the one year trial. Final

results for all trial participants will be available in the first

quarter of 2009. Genzyme is currently developing clinical trial

protocols for two Phase 3 studies of Genz-112638, and the company

anticipates initiating these studies early next year. Genzyme believes

that this oral product may offer a more convenient treatment option for

some patients.

Mipomersen for high-risk cardiovascular disease

Genzyme expects to finalize its license of mipomersen from Isis

Pharmaceuticals in the second quarter and subsequently communicate a

development plan for the product. Mipomersen is a lipid-lowering agent

being developed primarily for patients at significant cardiovascular

risk who are unable to achieve target cholesterol levels with statins

alone or who are intolerant of statins. The product offers an

innovative approach to addressing a serious unmet medical need, and

Genzyme believes it could prove to be the most effective lipid-lowering

agent for high risk cardiovascular disease patients for whom

conventional therapies are not sufficient. The product may provide

significant benefit over the standard of care and targets a well-defined

and severely ill patient population. Mipomersen is currently being

studied in a Phase 3 clinical trial involving patients with homozygous

familial hypercholesterolemia.

This press release contains forward-looking statements regarding Genzyme's financial outlook and business plans and strategies, including without limitation: its Q2 2008, YE 2008 and YE 20011 earnings guidance; its anticipated CAGR through 2011; its expectations for approval of Myo
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Genzyme to Build New R&D Center in Beijing
2. Genzyme Provides Update on Myozyme(R) Manufacturing
3. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
4. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
5. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
6. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
7. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
8. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
9. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
10. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
11. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... , May 27, 2015 RXi ... company focused on discovering and developing innovative therapies ... today announced that it has commenced a public offering ... purchase shares of its common stock and overallotment ... stock. The shares of common stock, warrants and ...
(Date:5/27/2015)... VANCOUVER , May 27, 2015 /CNW/ - CQDM, ... award close to $8.5M to six (6) multi-disciplinary and ... in neuroscience within their Focus on Brain strategic initiative. ... research entities involved as in-kind contributions. This exciting announcement ... Canadian Association for Neuroscience in the presence of Inez ...
(Date:5/27/2015)...  Northwest Biotherapeutics, Inc. (NASDAQ: NWBO ) ("NW ... for cancer, announced today that Dr. Marnix L. ... be making an Industry Expert Theater Presentation at the ... on Saturday, May 30, 2015, from 3 to ... McCormick Place. Dr. Bosch will provide an ...
(Date:5/27/2015)... The Medical Innovation Impact Index (MI3), ... on medical innovation, has been developed at the ... Dickinson University’s ( FDU ) Rothman Institute of Innovation ... to new FDA (Food & Drug Administration) draft guidance ... of certain medical devices. , “The main impediment ...
Breaking Biology Technology:RXi Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants 2RXi Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants 3Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 2Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 3Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 4Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 5Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 6Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 7Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 8Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 9Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 10NW Bio To Present Overview Of DCVax-Direct Phase I Trial In Chicago This Weekend 2NW Bio To Present Overview Of DCVax-Direct Phase I Trial In Chicago This Weekend 3Medical Innovation Impact Index Launched at Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) under the Rothman Institute 2
... LAFAYETTE, Ind. - Researchers are developing a new ... for advanced optical technologies, including ultrapowerful microscopes and ... cloak. The new materials could make possible ... an assistant professor of electrical and computer engineering ...
... forces between atoms and surfaces with unprecedented precision, University ... our understanding of the structure of atoms and improve ... Physical Review Letters . Van der Waals ... they are among the weakest known chemical interactions, so ...
... MINNEAPOLIS, Jan. 25, 2011 Thomas, McNerney & Partners, ... in life science and medical technology companies, today announced ... Schiess to Vice President. "These promotions are ... have made as members of the Thomas, McNerney investment ...
Cached Biology Technology:New materials may bring advanced optical technologies, cloaking 2Physicists take new look at the atom 2Physicists take new look at the atom 3Physicists take new look at the atom 4Thomas, McNerney & Partners Promotes Two Members of its Investment Team 2
(Date:5/11/2015)... , May 11, 2015 Curemark LLC, ... the start of a new Phase III double blind, ... its novel formulation, CM-AT, on all children ages 3-8 ... its FDA Phase III double blinded clinical trial for ... low levels of the digestive enzyme chymotrypsin. This new ...
(Date:5/7/2015)... May 7, 2015 Fingerprint ... FPC1022 and FPC1035, FPC,s smallest touch fingerprint sensors ... mainly considered for integration on the backside of ... OEMs increased possibilities to integrate touch fingerprint sensors ... also improves possibilities for module manufacturers to customize ...
(Date:4/27/2015)... ATLANTA , April 27, 2015  For more ... and trade show has been the premier worldwide event ... Systems 2015 is a must-attend event for any local, ... insight into the emerging commercial markets and current applications ... and innovations of this projected $48 billion industry, and ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5
... in China have an increased risk of schizophrenia, consistent ... deficiency and schizophrenia, according to a study in the ... violence and human rights. , Schizophrenia is a common ... hallucinations, and delusions, as well a as deterioration of ...
... scientists replace pricey solvents with cheap processing fluidsIn ... fluorescent quantum dots, scientists at Rice University have ... solvents used in quantum dot synthesis with cheaper ... , Rice's study, which was conducted under the ...
... conducted by a biologist at the University of California, San ... Animal Behaviour found that females of the species Uca crenulata ... their burrows before finally deciding on a mate. , “As ... sampling nearly as many candidates as the California fiddler crab,?said ...
Cached Biology News:Prenatal exposure to famine increases risk of schizophrenia 2The right drug at the right time 2The right drug at the right time 3Biologist Discovers What May Be World’s ‘Pickiest?Mates 2Biologist Discovers What May Be World’s ‘Pickiest?Mates 3
OSCP Antibody...
Smac/DIABLO (mouse) (CT) rabbit polyclonal antibody...
... polyclonal to Taura Syndrome Virus ... for all tested applications). ... peptide: VTNSEGSTIL MNDIPITNQN VVLSKNVTDN LFEVQDQALI ... to N terminal amino acids ...
Purified Mouse anti-Hu Actopaxin (pS8) Storage Temperature: Refrigerate(2 to 8C)...
Biology Products: